reported HRQoL at baseline, after 1 month, and end of treatment (n = 118), whereas physicians adjudicated AEs via CTCAE. Mean HRQoL scores were compared between patient randomization arms, as well as between those patients who did/did not receive dose modifications. Results Ninety-four percent had a CTCAE grade ≥1 for at least one treatment-associated AE, with 18% undergoing dose modification due to toxicity. Mean HRQoL scores did not significantly differ at each of the three time points. Patient and physician-adjudicated reports of nausea were significantly correlated at the start (r = 0.31, p < 0.01) and end of treatment (r = 0.42, p < 0.05). There were no significant correlations between need for dose modification and HRQoL scores.
Introduction
As greater degrees of toxicity have been generally deemed acceptable for cancer therapies when compared with other medical indications, an essential component of clinical trials in oncology is the accurate monitoring of these AEs to help ensure patient safety and inform decision-making related to treatment (Basch 2014; Basch et al. 2007 Basch et al. , 2015 Jensen and Snyder 2016; NCI 2001) . Patients who experience clinically significant AEs, commonly defined as grade 3 or 4 toxicities as captured by the Common Terminology Criteria for Adverse Events [CTCAE (NCI 2010) ], may be required to undergo protocol-mandated treatment breaks, dose modification, or treatment discontinuation (Belknap et al. 2010; Di Maio et al. 2016) . However, patients and clinicians may be willing to tolerate higher degrees of select AEs in cases where it is medically appropriate and if treatment is associated with potential meaningful improvements in clinical outcome (Trotti et al. 2007) .
As part of all National Cancer Institute (NCI)-sponsored cancer clinical trials in the USA, patient AEs are adjudicated by physicians via a rating system of descriptive terms known as the CTCAE (NCI 2010) . The CTCAE consists of a descriptive library individual items that represent discrete AEs (e.g., retinal tear, neutropenia, nausea) that are adjudicated by physicians using a 5-point ordinal scale, with each of the 5-point grading levels anchored to verbiage that describes a clinical scenario that represents that given level of severity (NCI 2010) . While the CTCAE was developed and updated based on a consensus-based process that did not include a formal validation of the individual items (Trotti et al. 2003) , the widespread adoption of this measure strengthens its value as a clinical assessment tool (Bruner et al. 2007) .
Driven by the recent push to capture and incorporate patient-reported outcomes (PRO) data into cancer clinical trials, the United States National Cancer Institute has developed a PRO version of the CTCAE to capture AEs amenable to patient reporting (PRO-CTCAE) Dueck et al. 2015; Hay et al. 2014) . However, based on our recent review of the literature, the association of PRO or health-related quality of life (HRQoL) data with clinician-adjudicated AEs has not been well established (Atkinson et al. 2016) .
We therefore sought to assess patient-reported HRQoL, and the degree to which it is associated with physicianadjudicated CTCAE, to establish a better understanding of how this information may inform the clinical trial decision process. To do this, we completed a secondary analysis of data from one clinical trial of patients with advanced uveal melanoma treated with either selumetinib, an investigational inhibitor of MEK1/2, or chemotherapy (Carvajal et al. 2014) . As part of this clinical trial, AEs were adjudicated by clinicians via CTCAE and patients reported their HRQoL using the Functional Assessment of Cancer Therapy-Melanoma [FACT-M (Cormier et al. 2008) ], a wellvalidated and widely used instrument for capturing HRQoL in patients with melanoma (Cornish et al. 2009 ).
Methods

Patients
The data for this analysis were obtained from a multicenter phase II trial (clinicaltrials.gov identifier: NCT01143402) of patients with documented metastatic uveal melanoma who had not received prior therapy with an MEK inhibitor, temozolomide, or dacarbazine who were enrolled between August 2010 and December 2013 (Carvajal et al. 2014) . Eligible patients were age 18 or older; had a life expectancy >3 months; were ambulatory [i.e., Eastern Cooperative Oncology Group performance status (ECOG PS) ≤1]; had measurable disease by RECIST version 1.1 (Eisenhauer et al. 2009 ); adequate organ function; and either untreated metastatic uveal melanoma or disease that progressed while receiving prior anticancer therapy based on physician opinion. The study protocol was approved by the Institutional Review Boards of each participating institution. All participants provided written informed consent at time of study enrollment.
Measures
Functional Assessment of Cancer Therapy-Melanoma [FACT-M (Cormier et al. 2008 )]-The FACT-M is a psychometrically sound instrument that is frequently utilized to assess HRQoL in clinical trials that include patients with melanoma (Grob et al. 2015) . The FACT-M consists of 43 items; 16 are specific to melanoma, with the remainder consisting of all items from the Functional Assessment of Cancer Therapy-General [FACT-G (Cella et al. 1993) ]. This measure yields scores for a number of subscales, including the overall FACT-General (FACT-G) total, physical (PWB), emotional (EWB), social (SWB), and functional well-being (FWB), as well as FACT-M total, a Trial Outcome Index (TOI) that is comprised of the summed PWB, FWB, and FACT-M subscales, and a Melanoma Score (MS). All included patients completed this assessment independently at each specified study time point.
Common Terminology Criteria for Adverse Events version 4 [CTCAE (NCI 2010)]-
The CTCAE consists of a library of 790 descriptive terms for clinician-adjudicated assessment of patient AEs related to cancer treatment. Each CTCAE term is assessed using a 5-point verbal descriptor grading scale, with each grade following a similar grading convention (i.e., 0 = not present, 1 = mild, 2 = moderate, 3 = severe and/or requiring medical intervention but not life-threatening, 4 = life-threatening consequences, and 5 = death). For the present study, diarrhea, edema, nausea, rash, and vomiting were selected as representative AEs because they are common toxicities associated with selumetinib that could conceivably make a significant impact to patient-reported HRQoL. Patient tolerance of elevated levels of these five AEs could be medically justified for continuing treatment. Nausea was the only AE assessed by both CTCAE and FACT-M.
Study design
Enrolled patients were either randomized to receive selumetinib, an oral MEK inhibitor, at a continual dose of 75 mg twice daily or chemotherapy. Those randomized to chemotherapy could receive selumetinib at objective disease progression. AEs were formally assessed at each physician evaluation, which occurred at baseline, every 2 weeks for 4 weeks, and every four weeks thereafter. Selumetinib dosage could be reduced based on non-hematologic physician-adjudicated AEs ≥ grade 3 (with the exception of alopecia) or patient platelets falling below 50,000/μL. Selumetinib was to be stopped for any grade 4 non-hematologic AE that a patient experienced, with the exception of alopecia, nausea, or vomiting. Selumetinib administration continued if there was no evidence of disease progression and if no grade 3 or 4 non-hematologic AEs were observed. Patients reported HRQoL via the FACT-M at baseline, 1 month post-treatment, and at end of treatment.
Statistical analysis
Independent samples t tests were used to evaluate mean FACT-M scores across the baseline, 1 month post-treatment, and end of treatment time points for those patients who had a physician-adjudicated at least one AE graded 1 or higher. Comparisons were made between patients who received selumetinib or chemotherapy, as well as those initially randomized to the chemotherapy arm who received selumetinib at disease progression, or required dose modifications due to toxicity. Multivariate analysis of variance (MANOVA) was used to compare mean FACT-M total, FACT-G total, PWB, EWB, SWB, FWB, TOI, and MS scores between treatment arms, as well as between those who did or did not receive a dosage modification. Additionally, Pearson correlations were calculated to between patient-reported nausea (via FACT-M) and physicianadjudicated nausea (via CTCAE), as well as between mean FACT-M scores and whether a patient had their dose reduced due to AEs.
Results
Patient characteristics
A total of 120 patients were included in the original study sample (median age = 62; 44% female); 101 patients were randomized to receive selumetinib (n = 50), or chemotherapy (n = 51), with 19 patients receiving selumetinib without randomization. Patient characteristics are displayed in Table 1 . All patients were ECOG PS 0 or 1. Nearly all patients (96%) had stage M1c disease, per American Joint Committee on Cancer cutaneous melanoma staging criteria. More than half of the sample (58%) had an elevated lactate dehydrogenase level. Twenty-three patients had previously undergone systematic therapy with ipilimumab (19%). Two patients did not complete the FACT-M at all assessment time points; therefore, the final analysis was based on 118 patients. Forty patients from the chemotherapy arm (80%) experienced disease progression and crossed over to the selumetinib arm. Table 2 displays the percentage of patients who had physician-adjudicated CTCAE toxicities within the two randomization arms, as well as the selumetinib without randomization arm. From the entire patient sample, 94% had a physician-adjudicated CTCAE for at least one of the following treatment-associated AEs of interest: diarrhea, edema, nausea, rash, or vomiting. For those patients randomized to chemotherapy, 40% experienced CTCAE grade 1 or 2 nausea and 24% experienced grade 1 or 2 vomiting. In the selumetinib randomization study arm, at least 20% of patients experienced CTCAE grade 1 or 2 toxicity for rash (76%), diarrhea (41%), nausea (37%), edema (29%), and vomiting (22%). Rash was also the most common physician-adjudicated toxicity in the selumetinib without randomization arm (67%), with those patients also experiencing edema (56%), diarrhea (44%), and nausea (39%). Only 2 patients, both from the selumetinib randomization arm, experienced a CTCAE grade 3 toxicity of interest (edema and rash), with no grade 4 toxicities of interest observed for any of these AEs. Twenty-two patients (18%) received a dosage modification based on physician-adjudicated AEs. Sixteen of these patients had their dosage reduced within one month (±30 days) of completing a study assessment time point (median = 22 days, range = 0-197 days). Eleven patients had dosage reduced based on grade 1/2 rash. Grade 1/2 edema led to dosage reduction in two patients, whereas grade 1/2 nausea and vomiting was responsible for dose modification in two patients. The remaining seven patients who underwent dose modification were for various other grade 1 or 2 non-hematologic AEs (e.g., ALT, cervical muscle weakness, dermatitis, fatigue, oral mucositis). Table 3 is a display of the FACT-M mean scores for the three assessment time points (i.e., baseline, 1 month posttreatment, and end of treatment) for those patients who had physician-adjudicated toxicity grade ≥1 (n = 111). Mean FACT-M scores did not significantly differ (p > 0.05) across selumetinib, chemotherapy, and crossover groups. All mean FACT-M subscores (i.e., FACT-M total, FACT-G total, PWB, EWB, SWB, FWB, TOI, and MS) did not differ between treatment arms (p 0.11-0.56) or between those who did or did not receive dose modifications (p 0.22-0.87).
Physician-adjudicated toxicities and dose modifications
Health-related quality of life measurements
We specifically assessed for any correlation between FACT-M scores and the need for dose modification due to toxicity, as those 22 individuals experiencing such toxicity might be expected to be impacted the greatest in terms of quality of life. No association with FACT-M score and the need for dose modification was observed in this population.
There were no significant correlations between dose modification status and FACT-M scores (r = 0.07, −0.01 and 0.03 for baseline, 1 month, and end of treatment, respectively). There were also no significant correlations between FACT-M scores and the timing of the dose modification (r −0.37-0.16, p's > 0.05), as defined by the number of days since the last assessment time point (i.e., completion of the most recent FACT-M questionnaire). Patient-reported nausea was significantly correlated with physician-adjudicated nausea at time of cycle 1, week 1 (r = 0.31, p < 0.01) and at end of treatment (r = 0.42, p < 0.05).
Discussion
Direct patient reporting of their symptomatic experience is an invaluable resource for understanding and monitoring treatment-related AEs as part of clinical trials in oncology (Basch 2010) . The US Food and Drug Administration (FDA) recognizes the importance of capturing this information as part of clinical outcome assessments in the drug development process (US Department of Health and Human Services 2014). The present study sought to assess patient-reported HRQoL between study arms as part of a randomized clinical trial and determine potential associations with clinician-adjudicated AEs. Despite the high rate of physician-adjudicated AEs (i.e., 94%) in this sample, patient-reported HRQoL was not significantly impacted by treatment. Patient and clinician-adjudicated assessments of nausea in this sample were statistically significantly associated, with a moderate relationship observed between these two independent rating sources. This finding is consistent with prior comparisons of patient and clinician-adjudicated AEs in other cancer disease types (Atkinson et al. 2016) .
When examining HRQoL in the subgroup of patients who received dosage reductions due to AEs, we found no significant differences as compared to those who did not receive dosage reductions, with no significant associations between dosage reduction and timing (in days) since the last HRQoL assessment. This provides additional evidence that, should the context be medically appropriate, the patient may be willing to tolerate that level of AEs and continue the current dosage. Should this information be available to a given clinician in real time, it would create an opportunity to discuss treatment options with the patient prior to any decisions being made regarding dosage reductions. This study has a number of limitations. Uveal melanoma is a relatively rare disease type and thus would be important to replicate these results across multiple, more prevalent diseases. Additionally, it is acknowledged that despite being one of the most widely accepted instruments for the collection of HRQoL in patients with melanoma, the FACT-M was not comprehensive in assessing all AEs relevant to uveal melanoma. The only AE associated with selumetinib that was assessed by FACT-M and CTCAE was nausea. While this trial only captured patient-reported information at three study assessment time points (i.e., baseline, 1 month, and end of treatment), future work that seeks to include patient-reported AEs and HRQoL in the clinical trial decision-making process should make use of wellestablished methods of electronic PRO (ePRO) data capture to assess this information at the time of patient clinic visits [particularly when dose adjustments are made (Abernethy et al. 2010)], as well as between visits to capture nuanced information about the patient day-to-day experience. Finally, it is acknowledged that this study may have insufficient power to detect differences in HRQoL between study arms. However, we believe that this attempt to understand how the patient-reported HRQoL may differ based on trial arm assignment, or whether dosage was modified, provides initial evidence to support the notion that this information should be considered as part of future clinical trials in oncology.
The present study illustrates the need for greater integration of patient reporting into cancer clinical trials. Given the availability of validated patient AE reporting measures [i.e., PRO-CTCAE Dueck et al. 2015; Hay et al. 2014) ] and standardized item banks for reporting additional symptoms and HRQoL [e.g., Patient-Reported Outcomes Measurement Information System (PROMIS; Cella et al. 2010) ], clinicians now have the tools to easily and seamlessly incorporate PRO and ePRO information into their clinical trial design for comparative effectiveness research (Basch et al. 2012 ). Additional research is needed to determine how to best integrate patient-reported AE and HRQoL data into clinical trial conduct and ultimately use this information to inform decision-making toward improving patient care.
